Avid Bioservices Inc (CDMO)

[Bungler]

This is co-branding. It is NOT "partnering by indication." If a patient had a disease for which the drug was a treatment, they could buy either Calan or Isoptin. How can they be forced to buy Calan if they have disease A and Isoptin if they have disease B? They are both the same drug, verapamil. That is my point. The BPs cannot control whose product is used for which indication, which is what I understand is the basis of the "partner-by-indication" theory. So far bidrite has been unable to answer my question how this would work in implementation. Therefore I do not see how PPHM could split up the Bavi market "by indication" - it makes no sense. Splitting up the market by geographical region does make sense.